Mutations in the Met ligand-binding domain (T230M/E168D), transmembrane or JM domain (R988C, T1010I) and the tyrosine kinase domain (T1275I, V14333I) have also been identified in HNSCC tumor samples [85], although their relative contribution to HNSCC progression remains to be determined. The gene discussed is MET; the disease is neoplasm.